Targeted inhibition of a 'signal jammer' protein may improve tumor response to immunotherapy
Targeted inhibition of a “signal jammer” protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent…